Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis
Arne Schäfer, Magdolna Szilvia Kovacs, Anna Eder, Axel Nigg, Martin Feuchtenberger
Topics & Concepts
MedicineRheumatoid arthritisMethotrexateVaccinationImmune systemImmunologyTofacitinibJanus kinaseAntibodyInternal medicineRheumatologyCytokineRheumatoid Arthritis Research and TherapiesSARS-CoV-2 and COVID-19 ResearchSpondyloarthritis Studies and Treatments